174 related articles for article (PubMed ID: 16892896)
41. Update on the therapy for myelodysplastic syndrome.
Kasner MT; Luger SM
Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
[TBL] [Abstract][Full Text] [Related]
42. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
43. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.
Loh ML
Br J Haematol; 2011 Mar; 152(6):677-87. PubMed ID: 21623760
[TBL] [Abstract][Full Text] [Related]
44. [Morphology: a critical phase in the diagnosis of myelodysplastic syndromes].
Zini G
Recenti Prog Med; 2014 Mar; 105(3):104-9. PubMed ID: 24675451
[TBL] [Abstract][Full Text] [Related]
45. MDS researchers seek treatments but find few.
Bankhead C
J Natl Cancer Inst; 2007 Jul; 99(13):996-7. PubMed ID: 17596568
[No Abstract] [Full Text] [Related]
46. Cytogenetic studies of Brazilian pediatric myelodysplastic syndrome cases: challenges and difficulties in a large and emerging country.
Velloso ED; Chauffaille ML; Peliçario LM; Tanizawa RS; Toledo SR; Gaiolla RD; Lopes LF
Braz J Med Biol Res; 2013 Jan; 46(1):85-90. PubMed ID: 23314345
[TBL] [Abstract][Full Text] [Related]
47. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
48. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
[TBL] [Abstract][Full Text] [Related]
49. [Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes].
Strullu M; Leblanc T; Lainey E
Bull Cancer; 2023 Nov; 110(11):1183-1195. PubMed ID: 37453833
[TBL] [Abstract][Full Text] [Related]
50. Treatment strategies in myelodysplastic syndromes.
Atallah E; Garcia-Manero G
Cancer Invest; 2008 Mar; 26(2):208-16. PubMed ID: 18259954
[TBL] [Abstract][Full Text] [Related]
51. A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system.
Mandel K; Dror Y; Poon A; Freedman MH
J Pediatr Hematol Oncol; 2002 Oct; 24(7):596-605. PubMed ID: 12368708
[TBL] [Abstract][Full Text] [Related]
52. Toxicity and outcome of children with treatment related acute myeloid leukemia.
Tabori U; Revach G; Nathan PC; Strahm B; Rachlis A; Shago M; Grant R; Doyle J; Malkin D
Pediatr Blood Cancer; 2008 Jan; 50(1):17-23. PubMed ID: 17252569
[TBL] [Abstract][Full Text] [Related]
53. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls.
Stachurski D; Smith BR; Pozdnyakova O; Andersen M; Xiao Z; Raza A; Woda BA; Wang SA
Leuk Res; 2008 Feb; 32(2):215-24. PubMed ID: 17675229
[TBL] [Abstract][Full Text] [Related]
54. Myelodysplastic syndromes in children.
Galaverna F; Ruggeri A; Locatelli F
Curr Opin Oncol; 2018 Nov; 30(6):402-408. PubMed ID: 30222640
[TBL] [Abstract][Full Text] [Related]
55. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution.
Breccia M; Latagliata R; Mengarelli A; Biondo F; Mandelli F; Alimena G
Haematologica; 2004 Jul; 89(7):866-8. PubMed ID: 15257942
[TBL] [Abstract][Full Text] [Related]
56. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients.
Luna-Fineman S; Shannon KM; Atwater SK; Davis J; Masterson M; Ortega J; Sanders J; Steinherz P; Weinberg V; Lange BJ
Blood; 1999 Jan; 93(2):459-66. PubMed ID: 9885207
[TBL] [Abstract][Full Text] [Related]
57. The myelodysplastic syndromes.
Nguyen PL
Hematol Oncol Clin North Am; 2009 Aug; 23(4):675-91. PubMed ID: 19577164
[TBL] [Abstract][Full Text] [Related]
58. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium.
Nakano TA; Lau BW; Dickerson KE; Wlodarski M; Pollard J; Shimamura A; Hofmann I; Sasa G; Elghetany T; Cada M; Dror Y; Ding H; Allen SW; Hanna R; Campbell K; Olson TS
Pediatr Blood Cancer; 2020 Oct; 67(10):e28652. PubMed ID: 32779892
[TBL] [Abstract][Full Text] [Related]
60. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
